Tumor‐reactive CD8<sup>+</sup> T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival
Julia Karbach(Memorial Sloan Kettering Cancer Center), Elke Jäger(Krankenhaus Nordwest), Nasser K. Altorki(Cornell University), Eric W. Hoffmann(Ludwig Cancer Research), Sacha Gnjatic(Tisch Hospital), Lloyd J. Old(Gynecologic Oncology Group), Jianda Yuan, Cathy A. Ferrara(NewYork–Presbyterian Hospital), Armin Bender(Georg Speyer Haus), Eckhart Weidmann(Krankenhaus Nordwest), Antje Neumann(Krankenhaus Nordwest)
Cited by 113
Related Papers
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k